Summary
The Hematologic Malignancies (HM) Program is dedicated to understanding the causes of blood cancers and developing successful gene, drug, and cellular treatment options to improve patient quality of life and survival.
Hematologic Malignancies
US · IL
National Cancer Institute (NCI)
grant
open
#nih-2P30CA015704-50
What they want
The program aims to: 1) create a deeper understanding of the biologic basis of hematological malignancies; 2) enhance knowledge of hematopoietic stem cell (HSC) biology and capabilities for gene therapy; 3) develop novel non-transplant treatments; and 4) improve the availability, safety, and efficacy of hematopoietic cell transplantation. This involves multidisciplinary expertise in hematology, immunology, genomics, clinical trial design/implementation, computation, and biostatistics.
Deliverables
- Deeper understanding of the biologic basis of hematological malignancies
- Enhanced knowledge of hematopoietic stem cell (HSC) biology
- Improved capabilities for gene therapy of hematological malignancies
- Development of novel non-transplant treatments
- Improved availability, safety, and efficacy of hematopoietic cell transplantation
- Research publications (1,655 papers in the previous grant period)
Key personnel
- Program Co-Leaders (non-transplant and transplant focus)
- Associate Program Leaders (leukemia biology and gene therapy focus)
- Clinicians
- Clinical scientists
- Basic scientists
- Experts in hematology
- Experts in immunology
- Experts in genomics
